BACKGROUND: Fourteen-day stored red blood cells (RBCs) containing an RBC-specific transgenic antigen (HOD) induce a recipient proinflammatory cytokine storm and are significantly more immunogenic compared to fresh RBCs. Given that recipient mice clear transfused stored RBCs more rapidly than fresh RBCs, we hypothesized that rapid RBC clearance was associated with adverse transfusion outcomes. STUDY DESIGN AND METHODS: HOD RBCs were treated by two distinct methods known to lead to rapid posttransfusion RBC clearance: phenylhydrazine or heat. HOD antigen expression was analyzed on the treated cells before transfusion, and RBC recovery, recipient cytokine response, and recipient anti-HOD alloimmunization response were measured after transfusion. RESULTS: Phenylhydrazine and heat treatment each led to near complete RBC clearance in recipients by 24 hours posttransfusion, without significantly altering HOD antigen expression on the transfused RBCs. Recipients of phenylhydrazine- or heat-treated RBCs had elevated circulating levels of keratinocyte-derived chemokine/CXCL-1, monocyte chemoattractant protein-1, and interleukin-6 after transfusion. Furthermore, phenylhydrazine- or heat-treated RBCs were significantly more immunogenic than control RBCs, with a mean 25.1- and 10.3-fold enhancement, respectively, of anti-HOD alloimmunization magnitude by flow cytometric crossmatch. CONCLUSIONS: Three separate insults to RBCs (storage, phenylhydrazine, or heat treatment) result in rapid posttransfusion clearance, with a recipient proinflammatory cytokine storm and enhanced alloimmunogenicity. These data are consistent with the hypothesis that rapid clearance of RBCs is causally involved in these outcomes and suggest that human donor RBCs with favorable posttransfusion clearance profiles may be less immunogenic.
BACKGROUND: Fourteen-day stored red blood cells (RBCs) containing an RBC-specific transgenic antigen (HOD) induce a recipient proinflammatory cytokine storm and are significantly more immunogenic compared to fresh RBCs. Given that recipient mice clear transfused stored RBCs more rapidly than fresh RBCs, we hypothesized that rapid RBC clearance was associated with adverse transfusion outcomes. STUDY DESIGN AND METHODS: HOD RBCs were treated by two distinct methods known to lead to rapid posttransfusion RBC clearance: phenylhydrazine or heat. HOD antigen expression was analyzed on the treated cells before transfusion, and RBC recovery, recipient cytokine response, and recipient anti-HOD alloimmunization response were measured after transfusion. RESULTS:Phenylhydrazine and heat treatment each led to near complete RBC clearance in recipients by 24 hours posttransfusion, without significantly altering HOD antigen expression on the transfused RBCs. Recipients of phenylhydrazine- or heat-treated RBCs had elevated circulating levels of keratinocyte-derived chemokine/CXCL-1, monocyte chemoattractant protein-1, and interleukin-6 after transfusion. Furthermore, phenylhydrazine- or heat-treated RBCs were significantly more immunogenic than control RBCs, with a mean 25.1- and 10.3-fold enhancement, respectively, of anti-HOD alloimmunization magnitude by flow cytometric crossmatch. CONCLUSIONS: Three separate insults to RBCs (storage, phenylhydrazine, or heat treatment) result in rapid posttransfusion clearance, with a recipient proinflammatory cytokine storm and enhanced alloimmunogenicity. These data are consistent with the hypothesis that rapid clearance of RBCs is causally involved in these outcomes and suggest that humandonor RBCs with favorable posttransfusion clearance profiles may be less immunogenic.
Authors: Christopher R Gilson; Teresa S Kraus; Eldad A Hod; Jeanne E Hendrickson; Steven L Spitalnik; Christopher D Hillyer; Beth H Shaz; James C Zimring Journal: Transfusion Date: 2009-08 Impact factor: 3.157
Authors: David M Baron; Binglan Yu; Chong Lei; Aranya Bagchi; Arkadi Beloiartsev; Christopher P Stowell; Andrea U Steinbicker; Rajeev Malhotra; Kenneth D Bloch; Warren M Zapol Journal: Anesthesiology Date: 2012-03 Impact factor: 7.892
Authors: Jeanne E Hendrickson; Eldad A Hod; Jennifer R Perry; Samit Ghosh; Prasanthi Chappa; Olufolake Adisa; Leslie S Kean; Solomon F Ofori-Acquah; David R Archer; Steven L Spitalnik; James C Zimring Journal: Transfusion Date: 2011-07-25 Impact factor: 3.157
Authors: Marianne E M Yee; Cassandra D Josephson; Anne M Winkler; Jennifer Webb; Naomi L C Luban; Traci Leong; Sean R Stowell; John D Roback; Ross M Fasano Journal: Transfusion Date: 2018-04-17 Impact factor: 3.337
Authors: Samuele Calabro; Antonia Gallman; Uthaman Gowthaman; Dong Liu; Pei Chen; Jingchun Liu; Jayendra Kumar Krishnaswamy; Manuela Sales L Nascimento; Lan Xu; Seema R Patel; Adam Williams; Christopher A Tormey; Eldad A Hod; Steven L Spitalnik; James C Zimring; Jeanne E Hendrickson; Sean R Stowell; Stephanie C Eisenbarth Journal: J Exp Med Date: 2016-05-16 Impact factor: 14.307
Authors: David R Gibb; Samuele Calabro; Dong Liu; Christopher A Tormey; Steven L Spitalnik; James C Zimring; Jeanne E Hendrickson; Eldad A Hod; Stephanie C Eisenbarth Journal: EBioMedicine Date: 2016-06-16 Impact factor: 8.143
Authors: Amanda L Richards; Kathryn Sheldon; Xiaoping Wu; David R Gruber; Krystalyn E Hudson Journal: Front Immunol Date: 2018-10-05 Impact factor: 7.561